Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2-Reference-Cited by-同舟云学术

Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2

Published:2021-06 Issue:3 Volume:161 Page:668-675
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Konecny Gottfried E.,Oza Amit M.,Tinker Anna V.,Oaknin Ana,Shapira-Frommer Ronnie,Ray-Coquard Isabelle,Aghajanian Carol,Coleman Robert L.,O'Malley David M.,Leary Alexandra,Chen Lee-may,Provencher Diane,Ma Ling,Brenton James D.,Castro Cesar,Green Michelle,Simmons Andrew D.,Beltman Jeri,Harding Thomas,Lin Kevin K.,Goble Sandra,Maloney Lara,Kristeleit Rebecca S.,McNeish Iain A.,Swisher Elizabeth M.,Xiao Jim J.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference26 articles.

1. Cancer Today;Global Cancer Observatory,2018

2. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas;Pennington;Clin. Cancer Res.,2014

3. Integrated genomic analyses of ovarian carcinoma;The Cancer Genome Atlas (TCGA) Research Network;Nature,2011

4. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2;Drew;J. Natl. Cancer Inst.,2011

5. Preclinical assessment of the PARP inhibitor rucaparib in homologous recombination deficient prostate cancer models;Nguyen;Cancer Res.,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial;eClinicalMedicine;2024-06

2. Effects of food and ethnicity on the pharmacokinetics of venadaparib, a next-generation PARP inhibitor, in healthy Korean, Caucasian, and Chinese male subjects;Investigational New Drugs;2023-12-15

3. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology;Clinical Pharmacokinetics;2023-08-16

4. PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy;International Journal of Gynecologic Cancer;2023-01-27

5. Bioanalytical Methods for Poly(ADP-Ribose) Polymerase Inhibitor Quantification: A Review for Therapeutic Drug Monitoring;Therapeutic Drug Monitoring;2023-01-12